---
title: "MKKGY.US (MKKGY.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MKKGY.US/news.md"
symbol: "MKKGY.US"
name: "MKKGY.US"
parent: "https://longbridge.com/en/quote/MKKGY.US.md"
datetime: "2026-05-21T06:19:50.901Z"
locales:
  - [en](https://longbridge.com/en/quote/MKKGY.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MKKGY.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MKKGY.US/news.md)
---

# MKKGY.US (MKKGY.US) — Related News

### [Merck KGaA Earnings Call Signals Cautious Upswing](https://longbridge.com/en/news/286486319.md)
*2026-05-15T00:45:01.000Z*
> Merck KGaA's Q1 earnings call highlighted a cautious optimism with 2.9% organic sales growth and improved EBITDA margins

### [Merck increases investment in China's assisted reproductive market. Merck Healthcare China Managing Director: Not winning in China will affect global business](https://longbridge.com/en/news/286450962.md)
*2026-05-14T17:43:12.000Z*
> Merck's Managing Director for Healthcare in China, Mu Ander, stated at the Asia-Pacific Reproductive Medicine Conference

### [Merck KGaA Lifts FY26 Outlook, Backs Positive Mid-term View, Despite Weak Q1; Stock Gains](https://longbridge.com/en/news/286247652.md)
*2026-05-13T11:04:03.000Z*
> Merck KGaA's shares rose approximately 8% after the company raised its fiscal 2026 guidance despite weak Q1 results. The

### [Merck KGaA raises profit expectations for 2026, driven by growth in laboratory business and core drug patent extensions boosting performance](https://longbridge.com/en/news/286213763.md)
*2026-05-13T07:15:34.000Z*
> Merck KGaA raised its profit forecast for 2026, expecting full-year EBITDA to reach between €5.7 billion and €6.1 billio

### [](https://longbridge.com/en/news/286212560.md)
*2026-05-13T07:07:02.000Z*
> Merck Group's stock price rose by 7.7% after the company raised its full-year performance forecast

### [A Look At Merck KGaA (XTRA:MRK) Valuation After Advancing Enpatoran To Global Phase 3 Lupus Trials](https://longbridge.com/en/news/285597327.md)
*2026-05-07T18:14:19.000Z*
> Merck KGaA (XTRA:MRK) has initiated global Phase 3 trials for enpatoran in lupus, marking a significant milestone. Despi

### [Merck KGaA (0O14) Gets a Buy from UBS](https://longbridge.com/en/news/285522532.md)
*2026-05-07T09:15:35.000Z*
> UBS analyst Matthew Weston has maintained a Buy rating on Merck KGaA, setting a price target of €150.00. Weston, a 4-sta